Analyst Ratings For Cytokinetics, Inc. (NASDAQ:CYTK)
Today, HC Wainwright set its price target on Cytokinetics, Inc. (NASDAQ:CYTK) to $21.00 per share.
There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Cytokinetics, Inc. (NASDAQ:CYTK) is Buy with a consensus target price of $13.80 per share, a potential 82.54% upside.
Some recent analyst ratings include
- 12/5/2018-Cytokinetics, Inc. (NASDAQ:CYTK) had its Buy rating reiterated by Cantor Fitzgerald with a $14.00 price target
- 2/20/2018-Cytokinetics, Inc. (NASDAQ:CYTK) had its Buy rating reiterated by Cowen with a $11.00 price target
- 11/29/2017-Cytokinetics, Inc. (NASDAQ:CYTK) gets downgraded to Buy by Needham & Company LLC with a price target of $12.00
- 11/21/2017-Cytokinetics, Inc. (NASDAQ:CYTK) had its Outperform rating reiterated by JMP Securities with a $13.00 price target
- On 11/5/2018 Robert I Blum, CEO, sold 4,000 with an average share price of $7.11 per share and the total transaction amounting to $28,440.00.
- On 11/1/2018 Fady Ibraham Malik, EVP, sold 1,500 with an average share price of $6.68 per share and the total transaction amounting to $10,020.00.
- On 10/5/2018 Robert I Blum, CEO, sold 4,000 with an average share price of $8.79 per share and the total transaction amounting to $35,160.00.
- On 10/4/2018 Fady Ibraham Malik, EVP, sold 1,500 with an average share price of $9.14 per share and the total transaction amounting to $13,710.00.
- On 9/6/2018 Fady Ibraham Malik, EVP, sold 1,500 with an average share price of $8.00 per share and the total transaction amounting to $12,000.00.
- On 9/5/2018 Robert I Blum, CEO, sold 4,000 with an average share price of $7.94 per share and the total transaction amounting to $31,760.00.
- On 8/3/2018 Robert I Blum, CEO, sold 4,000 with an average share price of $6.65 per share and the total transaction amounting to $26,600.00.
About Cytokinetics, Inc. (NASDAQ:CYTK)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
Recent Trading Activity for Cytokinetics, Inc. (NASDAQ:CYTK)
Shares of Cytokinetics, Inc. closed the previous trading session at 7,56 −0,36 4,55 % with 458600 shares trading hands.